Loza Matthew J, Metelitsa Leonid S, Perussia Bice
Jefferson Medical College, Kimmel Cancer Center, Department of Microbiology and Immunology, Philadelphia, PA, USA.
Eur J Immunol. 2002 Dec;32(12):3453-62. doi: 10.1002/1521-4141(200212)32:12<3453::AID-IMMU3453>3.0.CO;2-D.
A maturation-dependent change in phenotype and cytokine production from relatively immature CD161(-) or CD161(+), IL-13(+)IL-4(+), IFN-gamma(-), to mature CD161(+)CD56(+) IFN-gamma(+) cells occurs in primary human alpha-galactosyl ceramide-reactive CD1d-restricted natural killer T (NKT) cells under the control of IL-12 and other monokines. Modulation of this process upon alpha-galactosyl ceramide stimulation explains the opposite roles of NKT cells to drive type 1 and type 2 immune responses. Because the same developmental changes occurred and were similarly regulated in T cells, the data establish that NKT cells should no longer be considered a functionally unique regulatory subset. However, the results of their analysis can be taken as a model for immunotherapeutic approaches with T cells for which a nominal or surrogate antigen is defined.
在白细胞介素-12和其他单核因子的控制下,原代人α-半乳糖神经酰胺反应性CD1d限制性自然杀伤T(NKT)细胞会发生表型和细胞因子产生的成熟依赖性变化,即从相对不成熟的CD161(-)或CD161(+)、白细胞介素-13(+)白细胞介素-4(+)、γ干扰素(-)细胞转变为成熟的CD161(+)CD56(+)γ干扰素(+)细胞。α-半乳糖神经酰胺刺激对这一过程的调节解释了NKT细胞在驱动1型和2型免疫反应中相反的作用。由于T细胞中也发生了相同的发育变化且受到类似调节,这些数据表明NKT细胞不应再被视为功能独特的调节亚群。然而,对它们的分析结果可作为用T细胞进行免疫治疗方法的模型,其中定义了名义或替代抗原。
Eur J Immunol. 2002-12
Eur J Immunol. 2006-3
J Clin Invest. 2016-6-1
Biomed Res Int. 2014